WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories
SHANGHAI and NEW YORK, May 28, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been recognized by Life Science Leader for the third year, achieving 2020 CMO Leadership Awards in six criter...
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States
SHANGHAI and WORCESTER, Mass., May 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and the Worcester Business Development Corporation (WBDC) announced today the successful signing of a land deal for WuXi Bio...
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
SHANGHAI and HOUSTON, April 30, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, today announced a strategic collaboration agreement...
WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility
* First GMP facility in WuXi Biologics to use robotic aseptic filling line for biologics * Demonstrated diverse and flexible aseptic filling capability while maintaining high-quality and controlled filling accuracy as well as aseptic assurance WUXI, China, April 28, 2020 /PRNewswire/ -- WuXi ...
WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany
SHANGHAI and LEVERKUSEN, Germany, April 22, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisition deal with Bayer for a drug product manufacturing plant in Leverkusen,Ge...
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection
SUZHOU, China, April 13, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency (EMA), wi...
WuXi Biologics Achieved Remarkable Results in 2019
57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted EPS of RMB0.76 and Adjusted Diluted EPS of RMB0.91, Increasing 58.3% and 59.6% Backlog Increased 40.2% to US$5.1 Billion Milestone Payments Surg...
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland
DUNDALK, Ireland, March 11, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has completed the weather-tight seal o...
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19
SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Vir Biotechnology, Inc. ("Vir") (Nasdaq: VI...
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology comp...
WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that WuXi Vaccines, its joint venture with Shanghai ...
WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Vaccines, a new vaccine Contract Development and Manufacturing Organization (CDMO) established between WuXi Biologics (stock code: 2269.HK) and Shanghai Hile Bio-technology (stock code: 603718.SH) announced that it has entered into a strategic partners...
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak
SHANGHAI, Feb. 11, 2020 /PRNewswire/ -- WuXi Biologics is closely monitoring the coronavirus outbreak. Our management team is working vigilantly to execute our Business Continuity Plan to mitigate any potential risk. All three operating sites inChina, namely Wuxi, Shanghai and Suzhou, will resume...
WuXi Biologics Provides Operation Update Related to the Coronavirus Outbreak
SHANGHAI, Jan. 29, 2020 /PRNewswire/ -- The coronavirus outbreak is having a potentially significant social and economic impact inChina. WuXi Biologics is closely monitoring the coronavirus outbreak and is complying with guidance from the relevant authorities. Our management team is working vigil...
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
SHANGHAI, Jan. 29, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has stepped up its efforts in enabling the development of multipl...
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
* First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities * WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer SHANGHAI and LEVERKUSEN, Germany, Jan. 15, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a ...
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
* The 12th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing the power and versatile applications of WuXiBody™ in multiple therapeutic areas SHANGHAI and BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global o...
WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392
SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner OncoImmune on the U.S. Food and Drug ...
WuXi Biologics Receives "Special Award to Investors in Ireland" from Asia Matters
DUBLIN, Dec. 23, 2019 /PRNewswire/ -- December 23, 2019 – WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the "Special Awa...
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
DUNDALK, Ireland, Nov. 23, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in ...
